In its 2021 MD&A, AbbVie describes a number of initiatives and operational adjustments that support the firm’s ability to absorb strain and preserve or improve functioning despite adversity. Following the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization and realize approximately $2.5 billion of annual cost synergies, reflecting resource reconfiguration and strategic change processes. In response to the COVID-19 public health crisis, AbbVie continued to focus on employee safety by following guidance from state and local health authorities and implementing workplace safety measures, while closely managing manufacturing and supply chain resources around the world to ensure an uninterrupted supply of medicines, demonstrating operational flexibility, business continuity planning and crisis response mechanisms. The company emphasizes its strategy of delivering strong financial results, maximizing acquisition benefits, advancing and investing in its pipeline, and returning value to shareholders while ensuring a sustainable growth business over the long term, highlighting future orientation and strategic foresight. AbbVie expects to achieve strategic objectives through expense synergies realization, leverage from revenue growth, productivity initiatives in supply chain, and efficiency programs to optimize manufacturing, commercial infrastructure, administrative costs, and corporate expenses, indicating process adaptation and resource allocation capabilities. In assessing and mitigating credit risk, AbbVie monitors economic conditions, customer creditworthiness, and government funding, regularly communicates with customers, establishes allowances for credit losses based on estimates of future losses, and may utilize factoring arrangements, illustrating risk assessment and mitigation strategies. The company maintains financial resilience via a $4.0 billion unsecured revolving credit facility, compliance with covenants, sufficient financial flexibility to fund obligations through cash flows or debt issuance, a discretionary stock repurchase program, and contingency planning for long-term capital access. AbbVie also engages in collaborative and licensing arrangements with milestone-based payments contingent on development or commercial achievements, indicating dynamic resource management and inter-organizational collaboration. These measures collectively support the organization’s integrity and performance under pressures and disturbances, aligning with the system’s ability to maintain positive adjustment under challenging conditions.